{"id":"pexelizumab-in-conjunction-with-cabg","safety":{"commonSideEffects":[{"rate":"null","effect":"Thrombocytopenia"},{"rate":"null","effect":"Anemia"},{"rate":"null","effect":"Neutropenia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting C5, pexelizumab prevents the formation of the membrane attack complex, which is involved in the inflammatory response. This action is thought to reduce tissue damage and improve outcomes in patients undergoing cardiac surgery. Pexelizumab has been investigated for its potential to reduce the risk of acute kidney injury and other complications associated with cardiac surgery.","oneSentence":"Pexelizumab is a monoclonal antibody that inhibits the complement component 5 (C5) to reduce inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:49:50.009Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cardiac surgery for reduction of mortality and morbidity"}]},"trialDetails":[{"nctId":"NCT00088179","phase":"PHASE3","title":"Pexelizumab in Patients Undergoing Coronary Artery Bypass Grafting With Cardiopulmonary Bypass (PRIMO-CABG II)","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2004-07","conditions":"Coronary Artery Disease","enrollment":4000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"pexelizumab in conjunction with CABG","genericName":"pexelizumab in conjunction with CABG","companyName":"Alexion Pharmaceuticals, Inc.","companyId":"alexion-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pexelizumab is a monoclonal antibody that inhibits the complement component 5 (C5) to reduce inflammation. Used for Cardiac surgery for reduction of mortality and morbidity.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}